Free press releases distribution network?

Agency / Source: ChemImage Corporation

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



ChemImage Corporation Selected for $2 Million Defense Funding - ChemImage Corporation was selected for $2 Million in defense funding for the further development of Eye-Safe Stand-off Fusion Detection of chemical, biological, explosive and improvised explosive device threats - ChemImage.com
ChemImage Corporation Selected for $2 Million Defense Funding

 

PRZOOM - /newswire/ - Pittsburgh, PA, United States, 2015/12/23 - ChemImage Corporation was selected for $2 Million in defense funding for the further development of Eye-Safe Stand-off Fusion Detection of chemical, biological, explosive and improvised explosive device threats - ChemImage.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The funding for this contract comes as a part of the Fiscal Year 2010 Defense Appropriations Act that was approved by Congress and signed by the President this past weekend. Primary sponsorship for the funding came from U.S. Congressman Mike Doyle with Senate support from both Senators Arlen Specter and Bob Casey.

“We are excited for the opportunity to develop technology that has the potential to protect our troops and save lives,” said Dr. Matthew Nelson, Chief Scientist, who is Principal Investigator on the contract. “This is a real-time, on-the-move detection sensor development effort that aims to provide the capability for detection and identification of multiple threats in the presence of complex background environments.”

The system will combine multiple sensing technologies including Raman and shortwave infrared (SWIR) Chemical Imaging (i.e., hyperspectral imaging) using a sensor fusion engine developed by ChemImage. The system will help address eye-safety concerns associated with the use of lasers on the battlefield when humans are detected in the vicinity of the laser.

“The Eye-Safe project builds on demonstrated success of ChemImage standoff sensors as best-in-class for detection of hazardous materials, while addressing a critical hurdle in the successful deployment of this sensing technology”, said Dr. Patrick Treado, Founder and Chief Technology Officer at ChemImage.

About ChemImage

ChemImage Corporation (chemimage.com) is a world leader in hyperspectral imaging technologies, provides instrumentation, software, lab services and expert consulting to government, industrial and academic organizations. ChemImage offers these products and services for a range of applications including defense, security, pharmaceuticals, forensics and biomedical diagnostic research. Our state-of-the-art hyperspectral technology can help to reveal critical chemical and biological information about processes, products and services.

ChemImage’s main headquarters is located in Pittsburgh, Pennsylvania and houses research and development laboratories as well as engineering and manufacturing facilities.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: ChemImage Corporation

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


ChemImage Corporation Selected for $2 Million Defense Funding

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Linda Batykefer - ChemImage.com 
412-241-7335 x269 batykefer[.]chemimage.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ChemImage Corporation securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From ChemImage Corporation / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow Ltd

Visit  SKS Media | SKS Associates Ltd







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today